Pandorum Technologies, a biotechnology company developing programmable regenerative medicine, said it has closed an $18 million Series B financing to advance the clinical development of its tunable, exosome-based therapies, including its lead program Kuragenx, while scaling manufacturing and expanding operations across the U.S., Japan, and the Middle East.
The Bengaluru, India, and San Carlos, California-based company said the round was led by Protons Corporate, with participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, the Burman Family, and other investors. Pandorum also said that advisor and investor Bandana Kankani guided the transaction and helped structure the investment to align with the company’s value-creation plans.
Founded by Dr. Tuhin Bhowmick and Arun Chandru, Pandorum said its proprietary platform integrates biology, engineering, and computation to develop “tunable” regenerative exosome therapies designed to reprogram pathological tissue states, including inflammation and fibrosis, toward functional recovery. The company’s near-term focus is ocular surface diseases, including Stevens–Johnson Syndrome and neurotrophic keratitis, and it said Kuragenx has received U.S. FDA Orphan Drug Designation for those indications.
Pandorum said its clinical translation efforts are being led by clinicians, including Dr. Virender Singh Sangwan of Dr. Shroff’s Charity Eye Hospital in New Delhi, Dr. Shigeru Kinoshita of Kyoto Prefectural University of Medicine, and Dr. Ramez Haddadin and Dr. Satish Nadig of Northwestern Medicine in Chicago.
On manufacturing, Pandorum said it is pursuing a globally distributed strategy. The company cited a CDMO partnership with AGC Biologics in Italy to serve the U.S. and European markets, and a strategic collaboration with Nucelion Therapeutics in India, a subsidiary of Bharat Biotech, to support supply across the Asia-Pacific region. Pandorum said it is also exploring potential partnerships in the Middle East.
Beyond ophthalmology, the company said it is expanding its platform to target systemic inflammatory and degenerative diseases affecting organs, including the lung, liver, and nervous systems, as it works to broaden the applicability of its regenerative approach from single-tissue programs to multi-tissue repair.
KEY QUOTES
“Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core. Our approach treats tissue health, disease, and degeneration as a navigational challenge within an information-constrained biological landscape,”
“This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision- to heal fast and age slow.”
Dr. Tuhin Bhowmick, Co-Founder And CEO, Pandorum Technologies
“Congratulations to our team for this achievement. Regenerative medicine, particularly for corneal blindness, is a global necessity that knows no borders.”
Arun Chandru, Co-Founder, Pandorum Technologies
